Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival

Transplant Proc. 1999 Feb-Mar;31(1-2):1242-3. doi: 10.1016/s0041-1345(98)01979-4.
No abstract available

MeSH terms

  • Abatacept
  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD
  • Antigens, Differentiation / therapeutic use*
  • Blood Glucose / metabolism
  • CD40 Ligand
  • CTLA-4 Antigen
  • Cricetinae
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / surgery
  • Graft Survival / immunology*
  • Graft Survival / physiology
  • Humans
  • Immunoconjugates*
  • Immunosuppression Therapy / methods
  • Immunosuppressive Agents / therapeutic use*
  • Islets of Langerhans Transplantation / immunology*
  • Islets of Langerhans Transplantation / physiology
  • Male
  • Membrane Glycoproteins / immunology*
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred DBA
  • Recombinant Fusion Proteins / therapeutic use
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation
  • Blood Glucose
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Ctla4 protein, mouse
  • Immunoconjugates
  • Immunosuppressive Agents
  • Membrane Glycoproteins
  • Recombinant Fusion Proteins
  • CD40 Ligand
  • Abatacept